Literature DB >> 6974501

Perilymph total protein levels associated with cerebellopontine angle lesions.

A F O'Connor, M W France, A W Morrison.   

Abstract

The total protein levels in the perilymph of patients with acoustic neuromas, meningiomas, and Meniere's disease are contrasted. All specimens were obtained from the lateral semicircular canal during removal of the bony labyrinth. Any specimens with significant contamination by hemoglobin or serum proteins, as judged by the presence of hemoglobin/haptoglobin complexes, were discarded from this study. The findings of greatly increased perilymph protein levels in the tumor groups confirmed the reports of other workers. The levels in the Meniere's disease group compared favorably with the normal protein levels in perilymph. A very significant (p Less Than 0.05) difference between the acoustic neuroma group and the meningioma group is noted. This difference is probably tumor related, because in all cases of both groups, tumor entered and filled the internal auditory meatus.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6974501

Source DB:  PubMed          Journal:  Am J Otol        ISSN: 0192-9763


  15 in total

1.  Increased signal intensity of the cochlea on pre- and post-contrast enhanced 3D-FLAIR in patients with vestibular schwannoma.

Authors:  Masahiro Yamazaki; Shinji Naganawa; Hisashi Kawai; Takashi Nihashi; Hiroshi Fukatsu; Tsutomu Nakashima
Journal:  Neuroradiology       Date:  2009-12       Impact factor: 2.804

2.  Decreased vestibular signal intensity on 3D-FIESTA in vestibular schwannomas differentiating from meningiomas.

Authors:  Kazuhiro Ishikawa; Jun Haneda; Kouichirou Okamoto
Journal:  Neuroradiology       Date:  2012-10-16       Impact factor: 2.804

Review 3.  The Management and Imaging of Vestibular Schwannomas.

Authors:  E P Lin; B T Crane
Journal:  AJNR Am J Neuroradiol       Date:  2017-05-25       Impact factor: 3.825

4.  MRI of endolymphatic hydrops in patients with vestibular schwannomas: a case-controlled study using non-enhanced T2-weighted images at 3 Teslas.

Authors:  Aurélie Karch-Georges; Francis Veillon; Hella Vuong; Dominique Rohmer; Anne Karol; Anne Charpiot; Nicolas Meyer; Aina Venkatasamy
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-03-27       Impact factor: 2.503

5.  Automatic Segmentation of Intracochlear Anatomy in MR Images Using a Weighted Active Shape Model.

Authors:  Yubo Fan; Rueben A Banalagay; Nathan D Cass; Jack H Noble; Kareem O Tawfik; Robert F Labadie; Benoit M Dawant
Journal:  Annu Int Conf IEEE Eng Med Biol Soc       Date:  2021-11

6.  The clinical characteristics of tinnitus in patients with vestibular schwannoma.

Authors:  David M Baguley; Rachel L Humphriss; Patrick R Axon; David A Moffat
Journal:  Skull Base       Date:  2006-05

7.  Clinical significance of an increased cochlear 3D fluid-attenuated inversion recovery signal intensity on an MR imaging examination in patients with acoustic neuroma.

Authors:  D Y Kim; J H Lee; M J Goh; Y S Sung; Y J Choi; R G Yoon; S H Cho; J H Ahn; H J Park; J H Baek
Journal:  AJNR Am J Neuroradiol       Date:  2014-04-17       Impact factor: 3.825

8.  Increased cochlear fluid-attenuated inversion recovery signal in patients with vestibular schwannoma.

Authors:  R A Bhadelia; K L Tedesco; S Hwang; S H Erbay; P H Lee; W Shao; C Heilman
Journal:  AJNR Am J Neuroradiol       Date:  2008-01-31       Impact factor: 3.825

9.  MRI of endolymphatic hydrops in patients with intralabyrinthine schwannomas: a case-controlled study using non-enhanced T2-weighted images at 3 T.

Authors:  Aïna Venkatasamy; Pauline Bretz; Anne Karol; Aurélie Karch-Georges; Anne Charpiot; Francis Veillon
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-08-08       Impact factor: 2.503

10.  Predictors of Preoperative Tinnitus in Unilateral Sporadic Vestibular Schwannoma.

Authors:  Georgios Naros; Joey Sandritter; Marina Liebsch; Alex Ofori; Ahmed R Rizk; Giulia Del Moro; Florian Ebner; Marcos Tatagiba
Journal:  Front Neurol       Date:  2017-08-03       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.